• Leading physicians appointed to AdCella's clinical advisory board
• Advisory board brings expertise in oncology, mesothelioma, CAR-T cell therapies, haematology and immunology
• Advise on clinical trial design and positioning of BZDS1901 CAR-T therapy for mesothelioma and solid cancers

AdAlta Limited (ASX:1AD), developer of next generation cell and protein therapeutic products, has announced that its subsidiary AdCella Pty Ltd has convened a clinical advisory board to advise on the clinical development and Phase 1 trial design of BZDS1901, its mesothelin-targeted, armoured CAR-T cell therapy for mesothelioma and other solid cancers. The advisory board includes leading physicians with deep expertise in clinical oncology, mesothelioma, solid cancer CAR-T cell therapies, haematology and immunology. Their role is to review and advise on the clinical trial design for BZDS1901, provide guidance on current and emerging treatment standards, identify new knowledge in mesothelioma and other tumours that may be targeted, and help identify leading international clinical institutes and thought leaders for subsequent development. The board members include Associate Professor Emily Blyth, Professor Simon Harrison, Professor Ben Solomon, and Associate Professor Ben Tran, all of whom have extensive experience in their respective fields. AdCella anticipates additional members will join the advisory board in the future.

AdAlta is integrating Asia's prowess in T cell therapy development with the efficiency and quality of Australia's clinical and manufacturing ecosystem to create a pathway connecting 'Eastern' innovation in cellular immunotherapies with 'Western' regulated markets and patients. AdCella's first asset, BZDS1901, is a first-in-class CAR-T cell therapy for mesothelioma and other solid cancers that has demonstrated clinical potential, including difficult to achieve complete responses in advanced mesothelioma in China.